Introduction {#s1}
============

At the close of 2019, several patients with pneumonia of unknown cause were detected in Wuhan, China, and first reported to the World Health Organization Country Office in China on Dec 31, 2019 ([@B1]). Subsequently, the pathogen was identified as a novel enveloped RNA betacoronavirus ([@B2]) and named as "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) by the Coronavirus Study Group (CSG) of the International Committee on Taxonomy of Viruses ([@B3]). On Feb 11, 2020, WHO officially announced the disease caused by SARS-CoV-2 as "Coronavirus Disease 2019" (COVID-19) ([@B4]). Given the alarming levels of spread and severity of COVID-19, WHO characterizes COVID-19 as a pandemic ([@B5]), causing a total of 9,619,573 confirmed cases and 489,556 deaths globally as of June 26, 2020 ([@B6]).

Angiotensin-converting enzyme 2 (ACE2) was confirmed as the receptor that mediates the entry of SARS-CoV-2 into human cells, and the affinity of ACE2 protein with SARS-CoV-2 was 10--20 times that of SARS-CoV ([@B7]--[@B9]). The ACE2-expressing level in human tissues, using the RNA-seq method, showed that the level in urinary organs (kidney) was much higher (nearly 100-fold) than that in respiratory organs (lung) ([@B10]). In the kidney tissue, glomerular visceral ACE2 staining was observed ([@B11]). Theoretically, the kidney is a possible target organ that could be infected by SARS-CoV-2.

In this study, we reported the clinical characteristics of COVID-19 patients admitted to our center, focusing on kidney injury. We aimed to characterize the clinical characteristics and identify the potential risk factors of COVID-19-related AKI, in order to facilitate clinical management of COVID-19.

Materials and Methods {#s2}
=====================

Study Design and Participants
-----------------------------

We designed a retrospective cohort study. In-hospital patients with COVID-19 were pooled from the Sino-French branch of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology between Mar 9, 2020, and Mar 17, 2020. The Sino-French branch of Tongji Hospital, located in Wuhan, Hubei Province, was assigned responsibility for the treatments of severe COVID-19 patients by the Wuhan government on Jan 25, 2020. The hospital\'s wards were reprogrammed into a number of dedicated COVID-19 treatment units and taken over by medical teams from other parts of the country.

All patients who were enrolled in this study were diagnosed as COVID-19 according to the guidance provided by the Chinese National Health Commission ([@B12]). Patients with a history of maintenance dialysis, chronic kidney disease, or renal transplantation were excluded. The clinical observation was monitored up to Mar 17, 2020.

Data Collection
---------------

Data collection was conducted by two independent researchers (XYZ and JW), using a standardized data collection form. We extracted epidemiological, demographic, clinical, laboratory, treatment, and outcome data from electronic medical records. In order to track the changes in renal function of patients during hospitalization, we retrospectively recorded the laboratory findings of renal function in detail in chronological order. The researchers, ZXW and XL, adjudicated any discrepancy in interpretation between the two primary researchers and tracked the missing core data.

Definition
----------

Acute kidney injury (AKI) was diagnosed and classified according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria clinical practice guidelines ([@B13]). AKI was defined as an increase in serum creatinine (sCr) by 0.3 mg/dL (26.5 μmol/L) within 48 h or a 50% increase in sCr from the baseline within 7 days. The stage of AKI was classified by the sCr level, with increased 1.5--1.9, 2.0--2.9, and ≥3 times than baseline being defined as stages 1, 2, and 3, respectively ([@B13], [@B14]). Serum creatinine elevated was recognized as ≥104 μmol/L for males and ≥84 μmol/L for females, based on the reference range given by the Department of Laboratory of Tongji Hospital. In-hospital AKI was defined as the patient with normal sCr at admission, who developed AKI after admission. The clinical classification of COVID-19 was defined according to the Chinese management guideline for COVID-19 (trial version 7.0) ([@B12]). The general case was defined as patients with fever and other mild respiratory symptoms, combining imaging findings of pneumonia. The severe case was defined as either (i) polypnea, respiratory rate \>30 per min, or (ii) oxygen saturation ≤93%, or (iii) PaO~2~/FiO~2~ ratio ≤300 mmHg. The critical case was defined as meeting any criterion of the following: respiratory failure requiring mechanical ventilation; shock; and organ failure requiring admission to intensive care unit (ICU). Exposure history was defined as ever exposed to people with certain SARS-CoV-2 infection or the Wuhan Huanan Seafood Market. Coagulation disorder was defined as a 3-s extension of prothrombin time or a 5-s extension of activated partial thromboplastin time ([@B15]).

Statistical Analysis
--------------------

Continuous and categorical variables were presented as median (interquartile range) and n (%), respectively. To compare differences between AKI group and non-AKI group, we used the Mann--Whitney *U*-test (for continuous data), Pearson\'s χ^2^-test, or Fisher\'s exact test (for categorical data) where appropriate. The variables that were statistically significant (*p* \< 0.1) in the comparison of the two groups were analyzed by univariable logistic regression firstly, for screening the potential risk factors associated with AKI. The continuous variables (IL-2R, IL-6, TNF-α, PCT, hs-CRP, ESR, platelet count, albumin, NT-proBNP, hs-cTnI, eGFR) were converted into categorical ones, according to the normal reference range and the previous published literature ([@B15], [@B16]). Variables indicating significant associations with AKI in univariable logistic regression models (sex, clinical classification, IL-2R, IL-10, TNF-α, PCT, lymphocyte, NT-proBNP, hs-cTnI, eGFR, coagulation disorder, D-dimer) were the candidates of multivariable models. To avoid overfitting in the model and interaction effects between observed variables, six variables (COVID-19 clinical classification, lymphocyte percentage, procalcitonin, eGFR, coagulation disorder, D-dimer) were chosen for multivariable analysis. \[method = forward stepwise (LR), probability for entry stepwise = 0.05, probability for removal stepwise = 0.10, classification cutoff = 0.5, maximum iteration = 50, include constant in model\]. Data were analyzed using R statistical software (v.3.5.2; R Foundation for Statistical Computing, Vienna, Austria; <https://www.r-project.org>) and IBM SPSS Statistics for Windows version 23.0 (IBM Corporation, Armonk, NY, USA). A two-sided *p* \< 0.05 was considered statistically significant. The data in this study are available from the corresponding author.

Results {#s3}
=======

Baseline Characteristics
------------------------

We pooled 121 in-hospital patients between Mar 9, 2020, and Mar 17, 2020, and 116 eligible patients were included in this study. Five patients were excluded \[three cases with chronic kidney disease (one case receiving regular maintenance dialysis, one with diabetic nephropathy, one with nephrotic syndrome), one case diagnosed with tuberculous pericardial effusion after admission, one case missing the core medical record\] ([Figure 1](#F1){ref-type="fig"}). Of total patients, the median age was 62.0 (55.0, 69.0) years, exposure history was found in 40 (34.5%) cases, and the dominant onset symptoms were fever \[93, (81.9%)\] and cough \[70, (60.3%)\]. Between the two groups, the sex and COVID-19 clinical classification were significantly different, more male and critical cases were in the AKI group. The epidemiological, demographic, and clinical characteristics are presented in [Table 1](#T1){ref-type="table"}.

![Flowchart of the study. AKI, acute kidney injury.](fmed-07-00436-g0001){#F1}

###### 

Demographic, epidemiological, and clinical characteristics of the patients.

                             **Total, *n =* 116**                        **Non-AKI, *n* = 104**                      **AKI, *n =* 12**                ***p*-value**
  -------------------------- ------------------------------------------- ------------------------------------------- -------------------------------- ---------------
  Age (years)                62.0 (55.0, 69.0), *n =* 116                62.0 (55.0, 69.0), *n =* 104                  66.0 (56.8, 73.0), *n =* 12    0.386
      \<40                   9 (7.8%)                                    9 (8.7%)                                    0 (0.0%)                         0.595
      40--49                 5 (4.3%)                                    3 (2.9%)                                    2 (16.7%)                        0.083
      50--59                 32 (27.6%)                                  30 (28.8%)                                  2 (16.7%)                        0.58
      60--69                 42 (36.2%)                                  38 (36.5%)                                  4 (33.3%)                        --
      70--79                 19 (16.4%)                                  15 (14.4%)                                  4 (33.3%)                        0.206
     \>80                    9 (7.8%)                                    9 (8.7%)                                    0 (0.0%)                         0.595
  **Sex**                                                                                                                                             
      Male                   62 (53.4%)                                  52 (50.0%)                                  10 (83.3%)                       0.028
      Female                 54 (46.6%)                                  52 (50.0%)                                  2 (16.7%)                        
  Exposure history           40 (34.5%)                                  35 (33.7%)                                  5 (41.7%)                        0.816
  **Comorbidity**                                                                                                                                     
      Any                    62 (53~.~4%)                                53 (51.0%)                                  9 (75.0%)                        0.114
      Hypertension           47 (40.5%)                                  40 (38.5%)                                  7 (58.3%)                        0.309
      Diabetes               20 (17.2%)                                  17 (16.3%)                                  3 (25.0%)                        0.728
      CHD                    12 (10.3%)                                  9 (8.7%)                                    3 (25.0%)                        0.208
      CD                     7 (6.0%)                                    7 (6.7%)                                    0 (0.0%)                         --
      Malignancy             10 (8.6%)                                   9 (8.7%)                                    1 (8.3%)                         --
      Hyperuricemia          2 (1.7%)                                    1 (1.0%)                                    1 (8.3%)                         0.197
      Hypothyroidism         3 (2.6%)                                    1 (1.0%)                                    2 (16.7%)                        0.028
      COPD                   3 (2.6%)                                    2 (1.9%)                                    1 (8.3%)                         0.282
      Other                  9 (7.8%)[^\*^](#TN1){ref-type="table-fn"}   9 (8.7%)[^\*^](#TN1){ref-type="table-fn"}   0 (0.0%)                         0.595
  Fever                      93 (80.2%)                                  81 (77.9%)                                  12 (100.0%)                      0.151
  Cough                      70 (60.3%)                                  64 (61.5%)                                  6 (50.0%)                        0.644
  Sputum                     30 (25.9%)                                  28 (26.9%)                                  2 (16.7%)                        0.674
  Chest distress             17 (14.7%)                                  13 (12.5%)                                  4 (33.3%)                        0.133
  Dyspnea                    28 (24.1%)                                  22 (21.1%)                                  6 (50.0%)                        0.064
  Headache                   8 (6.9%)                                    8 (7.7%)                                    0 (0.0%)                         --
  Myalgia                    11 (9.5%)                                   9 (8.7%)                                    2 (16.7%)                        0.318
  Fatigue                    38 (32.8%)                                  33 (31.7%)                                  5 (41.7%)                        0.712
  Hypersomnia                2 (1.7%)                                    1 (1.0%)                                    1 (8.3%)                         0.197
  Nausea                     7 (6.0%)                                    5 (4.8%)                                    2 (16.7%)                        0.154
  Anorexia                   15 (12.9%)                                  13 (12.5%)                                  2 (16.7%)                        --
  Diarrhea                   27 (23.3%)                                  26 (25.0%)                                  1 (8.3%)                         0.351
  Asymptomatic               3 (2.6%)                                    3 (2.9%)                                    0 (0.0%)                         --
  Body temperature (°C)      37.8 (36.7, 38.5)                           37.7 (36.6, 38.5)                           37.9 (36.8,38.5)                 0.72
      ≤37.3                  44 (37.9%)                                  40 (38.5%)                                  4 (33.3%)                        0.974
      37.4--38               32 (27.6%)                                  27 (26.0%)                                  5 (41.7%)                        0.417
      38.1--39               35 (30.2%)                                  33 (31.7%)                                  2 (16.7%)                        0.457
     ≥39.1                   5 (4.3%)                                    4 (3.8%)                                    1 (8.3%)                         0.427
  SBP (mmHg)                 132.0 (120.0, 141.0), *n =* 116             130.0 (120.0, 141.0), *n =* 104             137.5 (131.3, 148.8), *n =* 12   0.121
  DBP (mmHg)                 80.5 (75.0, 90.0), *n =* 116                80.0 (74.3, 90.0), *n =* 104                84.0 (76.3, 90.0), *n =* 12      0.43
  Respiratory rate (bpm)     20.0 (20.0, 24.0), *n =* 116                20.0 (20.0, 22.8), *n =* 104                20.5 (20.0, 27.5), *n =* 12      0.302
     \>24                    30 (25.9%)                                  25 (24.0%)                                  5 (41.7%)                        0.331
  Pulse (bpm)                91.0 (80.0, 105.0), *n =* 116               90.0 (80.0, 105.0), *n =* 104               97.5 (87.0, 117.8), *n =* 12     0.149
  **Type of diagnosis**                                                                                                                               
      Clinical diagnosis     39 (33.6%)                                  35 (33.7%)                                  4 (33.3%)                        --
      Laboratory diagnosis   77 (66.4%)                                  69 (66.3%)                                  8 (66.7%)                        --
  Clinical classification                                                                                                                             --
      Noncritical            93 (80.2%)                                  88 (84.6%)                                  5 (41.7%)                        0.002
      Critical               23 (19.8%)                                  16 (15.4%)                                  7 (58.3%)                        

*Others including coma, pulmonary tuberculosis, benign prostatic hyperplasia, hemoptysis, hepatitis B, hyperlipidemia, anemia, chronic gastric, asthma. Continuous variables were presented as median (IQR). Categorical variables were presented as n (%), and percentages do not total 100% owing to missing data. AKI, acute kidney injury; CHD, coronary heart disease; CD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; DBP, diastolic blood pressure*.

Laboratory and Radiographic Findings on Admission
-------------------------------------------------

The inflammatory indicators, interleukin-2R \[553.50 (319.25, 897.75) U/mL\], interleukin-6 \[15.57 (3.07, 39.62) pg/mL\], tumor necrosis factor-α \[8.40 (5.95, 11.75) pg/mL\], procalcitonin \[0.06 (0.03, 0.15) ng/mL\], and high-sensitivity C-reactive protein \[40.10 (12.65, 124.10) mg/L\], were significantly higher than the normal range and higher in the AKI group than in the non-AKI group (*p* = 0.006, *p* = 0.017, *p* = 0.002, *p* \< 0.0001, *p* = 0.035). The findings of the blood routine test on admission showed decreased lymphocyte \[percentage 14.25 (7.83, 23.23)%, count 0.83 (0.53, 1.34) × 10^9^/L\] and increased neutrophil \[percentage 78.40 (64.68, 86.55)%, count 4.82 (3.42, 7.53) × 10^9^/L\]. N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin I (hs-cTnI), prothrombin time (PT), activated partial thromboplastin time (APTT), and D-dimer level on admission were also found significantly higher in the AKI group (*p* = 0.005, *p* = 0.005, *p* = 0.001, *p* = 0.003, *p* = 0.005). Laboratory and radiographic findings of patients on admission are summarized in [Table 2](#T2){ref-type="table"}.

###### 

Laboratory and radiographic findings of the patients on admission.

                                        **Total, *n =* 116**                 **Non-AKI, *n =* 104**              **AKI, *n =* 12**                     ***p*-value**   **Normal range**
  ------------------------------------- ------------------------------------ ----------------------------------- ------------------------------------- --------------- ---------------------------------
  SARS-CoV-2 IgM (AU/mL)                49.34 (13.96, 106.47), *n =* 82      50.8 (15.2, 106.5), *n =* 78        28.00 (1.90, 199.23), *n =* 4         0.451           
  SARS-CoV-2 IgG (AU/mL)                169.76 (108.52, 190.63), *n =* 82    169.99 (109.44, 191.71), *n =* 78   129.35 (26.59, 183.39), *n =* 4       0.401           ≤10
  SARS-CoV-2 IgG/IgM                    2.82 (1.29, 7.11), *n =* 82          2.81 (1.19, 6.21), *n =* 78         8.36 (1.47, 21.32), *n =* 4           0.301           ≤10
  IL-1β, ≥5 (pg/mL)                     39 (33.6%)                           34 (32.7%)                          5 (41.7%)                             0.764           \<5
  IL-2R (U/mL)                          553.50 (319.25, 897.75), *n =* 92    537.00 (316.00, 861.00), *n =* 82   1172.50 (715.00, 2285.75), *n =* 10   0.006           223--710
      \<710                             36 (31.0%)                           28 (26.9%)                          8 (66.7%)                             0.013           
  IL-6 (pg/mL)                          15.57 (3.07, 39.62), *n =* 96        11.61 (2.71, 37.82), *n =* 86       32.85 (20.15, 401.90), *n =* 10       0.017           \<7
      \<7                               63 (54.3%)                           54 (51.9%)                          9 (75.0%)                             0.129           
  IL-8 (pg/mL)                          15.95 (7.98, 43.75), *n =* 90        14.40 (7.55, 42.00), *n =* 80       22.45 (16.08, 62.13), *n =* 10        0.284           \<62
  IL-10, ≥9.1 (pg/mL)                   22 (19.0%)                           17 (16.3%)                          5 (41.7%)                             0.084           \<9.1
  TNF-α (pg/mL)                         8.40 (5.95, 11.75), *n =* 93         8.20 (5.78, 10.53), *n =* 82        15.70 (9.20, 19.10), *n =* 11         0.002           \<8.1
      \<8.1                             52 (44.8%)                           42 (40.4%)                          10 (83.3%)                            0.005           
  PCT (ng/mL)                           0.06 (0.03, 0.15), *n =* 97          0.05 (0.03, 0.12), *n =* 85         1.08 (0.08, 1.78), *n =* 12           \<0.0001        0.02--0.05
      \<0.05                            57 (49.1%)                           57 (54.8%)                          0 (0.0%)                              \<0.0001        
      0.05--0.1                         27 (23.3%)                           23 (22.1%)                          4 (33.3%)                             0.61            
     \>0.1                              32 (27.6%)                           24 (23.1%)                          8 (66.7%)                             0.004           
  hs-CRP (mg/L)                         40.10 (12.65, 124.10), *n =* 92      36.10 (9.70, 116.30), *n =* 81      105.50 (39.10, 174.00), *n =* 11      0.035           \<1
     ≥1                                 85 (73.3%)                           74 (71.2%)                          11 (91.7%)                            0.24            
  ESR (mm/H)                            32.0 (17.0, 65.5), *n =* 52          28.0 (15.3, 58.0), *n =* 46         55.5 (31.0, 84.8), *n =* 6            0.094           2--20
      Elevated                          33 (28.4%)                           27 (25.0%)                          6 (50.0%)                             0.159           
  Leukocyte count (× 10^9^ per L)       6.73 (4.93, 9.92), *n =* 110         6.55 (4.87, 9.37), *n =* 99         12.73 (5.16, 19.20), *n =* 11         0.043           3.5--9.5\*10^9^
  Neutrophil percentage                 78.40 (64.68, 86.55), *n =* 110      75.60 (64.10, 86.20), *n =* 99      83.20 (76.30, 93.30), *n =* 11        0.041           40--75
  Neutrophil count (× 10^9^ per L)      4.82 (3.42, 7.53), *n =* 104         4.75 (3.37, 7.07), *n =* 95         6.85 (3.75, 14.99), *n =* 9           0.087           1.8--6.3\*10^9^
  Lymphocyte percentage                 14.25 (7.83, 23.23), *n =* 108       14.70 (8.23, 24.58), *n =* 96       7.50 (3.58, 11.13), *n =* 12          0.003           20--50
  Lymphocyte count (× 10^9^ per L)      0.83 (0.53, 1.34), *n =* 107         0.91 (0.54, 1.35), *n =* 96         0.59 (0.42, 0.83), *n =* 11           0.1             1.1--3.2\*10^9^
  Erythrocyte count, (× 10^12^ per L)   4.11 (3.63, 4.51), *n =* 104         4.14 (3.69, 4.51), *n =* 96         3.75 (2.73, 4.65), *n =* 8            0.487           F 3.8--5.1 (M 4.3--5.8)\*10^12^
  Hemoglobin (g/L)                      125.0 (108.0, 134.5), *n =* 109      127.0 (110.0, 134.5), *n =* 97      106.0 (83.8, 137.8), *n =* 12         0.089           F 115--150 (M 130--175)
  Platelet count (× 10^9^ per L)        196.00 (157.25, 261.00), *n =* 102   199.50 (158.50, 269.00), *n =* 92   155.50 (121.00, 197.50), *n =* 10     0.021           125--350\*10^9^
      \<125                             12 (10.3%)                           9 (8.7%)                            3 (25.0%)                             0.208           
  Glucose (μmol/L)                      6.57 (5.50, 8.74), *n =* 102         6.57 (5.37, 8.73), *n =* 91         6.41 (5.80, 9.19), *n =* 11           0.608           4.11--6.05
  Ferroprotein (μg/L)                   570.8 (276.5, 1241.0), *n =* 81      542.0 (268.0, 1199.5), *n =* 74     1264.0 (416.0, 1652.0), *n =* 7       0.168           F 15--150 (M 30--400)
  ALT (U/L)                             27.0 (18.0, 44.0), *n =* 106         28.0 (18.5, 44.0), *n =* 97         23.0 (15.5, 38.5), *n =* 9            0.411           F \<33 (M \<41)
  AST (U/L)                             27.0 (21.0, 39.0), *n =* 108         27.0 (21.0, 38.0), *n =* 97         26.7 (21.0, 48.0), *n =* 11           0.655           F \<32 (M \<40)
  ALP (U/L)                             71.0 (59.0, 91.3), *n =* 102         71.0 (57.5, 89.0), *n =* 92         72.0 (62.8, 171.5), *n =* 10          0.251           F 35--105 (M 40--130)
  LDH (U/L)                             302.0 (220.0, 403.0), *n =* 103      291.5 (212.3, 400.0), *n =* 92      356.0 (311.0, 423.0), *n =* 11        0.051           F 135--214 (M 135--225)
  Albumin (g/L)                         33.75 (29.98, 39.15), *n =* 110      34.20 (30.90, 39.40), *n =* 99      28.30 (25.70, 33.80), *n =* 11        0.013           35--52
     ≤25                                14 (12.1%)                           10 (9.6%)                           4 (33.3%)                             0.055           
  Globulin (g/L)                        33.4 (30.1, 36.8), *n =* 96          33.1 (30.4, 36.4), *n =* 88         35.9 (27.8, 42.7), *n =* 8            0.533           20--35
  Total bilirubin (μmol/L)              9.55 (6.93, 14.25), *n =* 102        9.60 (6.85, 14.45), *n =* 93        8.30 (6.95, 13.75), *n =* 9           0.728           F \<21 (M \<26)
  Total cholesterol (mmol/L)            3.65 (3.12, 4.34), *n =* 95          3.65 (3.13, 4.43), *n =* 89         3.65 (2.68, 4.63), *n =* 6            0.68            \<5.18
  NT-proBNP                             251.0 (64.0, 867.3), *n =* 82        220.5 (49.5, 683.3), *n =* 72       1250.5 (254.5, 3072.8), *n =* 10      0.005           --
      Elevated                          29 (25.0%)                           22 (21.2%)                          7 (58.3%)                             0.014           
  hs-cTnI (pg/mL)                       11.15 (5.50, 24.72), *n =* 74        10.90 (4.80, 19.50), *n =* 63       78.40 (8.90, 241.90), *n =* 11        0.005           F ≤15.6 (M 34.2)
      Elevated                          20 (17.2%)                           14 (13.5%)                          6 (50.0%)                             0.006           
  PT (s)                                14.3 (13.5, 15.1), *n =* 104         14.1 (13.5, 14.9), *n =* 92         15.5 (14.5, 16.2), *n =* 12           0.001           11.5--14.5
  APPT (s)                              40.1 (36.2, 45.0), *n =* 93          39.7 (35.7, 44.4), *n =* 83         45.8 (42.4, 52.9), *n =* 10           0.003           29.0--42.0
  Coagulation disorder                  19 (16.4%)                           14 (13.5%)                          5 (41.7%)                             0.037           
  D-dimer (μg/mL)                       1.31 (0.49, 4.31), *n =* 106         1.25 (0.48, 3.18), *n =* 94         4.80 (1.47, 18.34), *n =* 12          0.005           \<0.5
      Ground-glass opacity              23 (19.8%)                           20 (19.2%)                          3 (25.0%)                             0.926           
      Patchy shadow                     6 (5.2%)                             5 (4.8%)                            1 (8.3%)                              0.489           
      Infection indicated               87 (7.5%)                            79 (76.0%)                          8 (66.7%)                             0.725           

*Continuous variables were presented as median (IQR) and the number of cases available was noted. Categorical variables were presented as n (%), and percentages do not total 100% owing to missing data. AKI, acute kidney injury; IL, interleukin; TNF-α, tumor necrosis factor-α; PCT, procalcitonin; hs-CRP, high-sensitivity C-reactive protein; ESR, erythrocyte sedimentation rate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; LDH, lactic dehydrogenase; NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-cTnI, high-sensitivity cardiac troponin I; PT, prothrombin time; APTT, activated partial thromboplastin time*.

Treatments and Outcomes
-----------------------

Of the entire series, antibiotics were administered in 97 (83.6%) cases, corticosteroids were administered in 63 (54.3%) cases, and 106 (91.4%) received antiviral treatment (including 36 cases accepting Chinese traditional medicine). As of Mar 17, the total observation period was 28.0 (13.5, 41.0) days, while 108 (93.1%) patients were still in hospital. Among them, 19 patients were treated in the ICU and 89 in the general ward. The treatments and outcomes were compared between the sCr elevated group and sCr normal group and summarized in [Table S1](#SM1){ref-type="supplementary-material"}.

Kidney Injury and Associated Risk Factors
-----------------------------------------

The dynamic profiles of sCr and eGFR of all patients, the sCr elevated group, and the sCr normal group are shown in [Figure S1](#SM1){ref-type="supplementary-material"}. On admission, 21 (18.1%) were observed with elevated sCr. Hematuria was observed in 24 (20.7%) patients \[(+) in 16 (13.8%) cases; (++ to +++) in 8 (6.9%)\]. Proteinuria was observed in 25 (21.6%) patients \[(+) in 19 (16.4) cases; (++ to +++) in 6 (5.2%) cases\] ([Table 3](#T3){ref-type="table"}).

###### 

Laboratory findings of the kidney function of the patients on admission.

                            **Total, *n =* 116**               **Non-AKI, *n =* 104**             **AKI, *n =* 12**                ***p*-value**   **Normal range**
  ------------------------- ---------------------------------- ---------------------------------- -------------------------------- --------------- -------------------------
  Potassium (mmol/L)        4.21 (3.81, 4.53), *n =* 98        4.20 (3.81, 4.52), *n =* 89        4.37 (3.86, 5.33), *n =* 9       0.449           3.5--5.10
  Sodium (mmol/L)           139.8 (136.0, 141.7), *n =* 99     139.9 (136.9, 141.6), *n =* 91     135.6 (130.2, 143.0), *n =* 8    0.372           136--145
  sCr (μmol/L)              67.5 (55.0, 82.0), *n =* 114       66.0 (54.0, 79.3), *n =* 102       127.0 (66.3, 166.5), *n =* 12    \<0.0001        F 45--84 (M 59--104)
  eGFR (mL/min/1.73 m^2^)   95.52 (79.56, 117.04), *n =* 114   98.95 (82.02, 117.93), *n =* 102   53.49 (38.62, 87.78), *n =* 12   \<0.0001        \>90
      \<60                  7 (6.0%)                           3 (2.9%)                           4 (33.3%)                        0.002           
  BUN (mmol/L)              5.10 (3.90, 6.37), *n =* 108       4.80 (3.55, 6.25), *n =* 97        8.70 (5.80, 14.70), *n =* 11     \<0.0001        F 3.1--8.8 (M 1.7--8.3)
  Hematuria                                                                                                                                        --
      Any positive          24 (20.7%)                         20 (19.2%)                         4 (33.3%)                        0.444           
      +                     16 (13.8%)                         13 (12.5%)                         3 (25.0%)                        0.455           
      ++ \~ +++             8 (6.9%)                           7 (6.7%)                           1 (8.3%)                         0.595           
  Urinary leukocyte                                                                                                                                --
      Any positive          18 (15.5%)                         16 (15.4%)                         2 (16.7%)                        --              
      +                     8 (6.9%)                           7 (6.7%)                           1 (8.3%)                         0.595           
      ++ \~ +++             10 (8.6%)                          9 (8.7%)                           1 (8.3%)                         --              
  Proteinuria                                                                                                                                      --
      Any positive          25 (21.6%)                         19 (18.3%)                         6 (50.0%)                        0.031           
      +                     19 (16.4%)                         16 (15.5%)                         3 (25.0%)                        0.66            
      ++ \~ +++             6 (5.2%)                           3 (2.9%)                           3 (25.0%)                        0.014           

*Continuous variables were presented as median (IQR), and the number of cases available was noted. Categorical variables were presented as n (%), and percentages do not total 100% owing to missing data. BUN, blood urea nitrogen; sCr, serum creatinine; eGFR, estimated glomerular filtration rate*.

Over the observation period, 12 (10.3%) patients met the diagnostic criteria of AKI \[9 (7.8%) of stage 1 and 3 (2.6%) of stage 2)\], including 7 (6.0%) patients of the sCr elevated group. Of the sCr normal group, AKI were developed in 5 (4.3%) patients \[3 (2.6%) of stage 1 and 2 (1.7%) of stage 2\], recorded as in-hospital AKI. Four (80.0%) of five in-hospital AKI occurring after the patient\'s health status worsened. A reduction in oxygen saturation was observed, while two patients developed respiratory failure and two acute respiratory distress syndrome. One of the five in-hospital AKI was recognized as a result of the side effects of the antivirus drug. Renal function recovered was observed in four patients, while one patient received continuous renal replacement therapy (CRRT) ([Tables S2](#SM1){ref-type="supplementary-material"}, [S3](#SM1){ref-type="supplementary-material"}).

In univariable analysis, sex, clinical classification, IL-2R, IL-10, TNF-α, PCT, neutrophil percentage, lymphocyte percentage, NT-proBNP, hs-cTnI, eGFR, coagulation disorder, and D-dimer were associated with AKI ([Table 4](#T4){ref-type="table"}). Multivariable regression showed increasing odds of COVID-19-related AKI associated with COVID-19 clinical classification (OR = 8.155, 95% CI = 1.848--35.983, ref = non-critical, *p* = 0.06), procalcitonin more than 0.1 ng/mL (OR = 4.822, 95% CI = 1.095--21.228, *p* = 0.037), and eGFR \<60 mL/min/1.73 m^2^ (OR = 13.451, 95% CI = 1.617--111.891, *p* = 0.016) ([Table 4](#T4){ref-type="table"}).

###### 

Risk factors associated with COVID-19-related AKI.

                                                           **Univariable**   **Multivariable**                                             
  -------------------------------------------------------- ----------------- ------------------- ------- -------- ------- -------- ------- ---------
  Age, per 1 year increased, *n =* 116                     0.634             1.012               0.964   1.063    --      --       --      --
  Sex, ref = female, *n =* 116                             0.044             5.000               1.044   23.939   --               --      --
  Comorbidity present, ref = not present, *n =* 116        0.127             2.887               0.739   11.270   --      --       --      --
  Clinical classification, ref = non-critical, *n =* 116   0.002             7.700               2.173   27.288   0.006   8.155    1.848   35.983
  IL-2R, ref = \<710 U/mL, *n =* 116                       0.009             5.429               1.515   19.448   --      --       --      --
  IL-10, ref = \<9.1 pg/mL, *n =* 116                      0.044             3.655               1.037   12.885   --      --       --      --
  TNF-α, ref = \<8.1 pg/mL, *n =* 116                      0.012             7.381               1.539   35.403   --      --       --      --
  PCT, ref = \<0.1 ng/mL, *n =* 116                        0.004             6.667               1.846   24.073   0.037   4.822    1.095   21.228
  Neutrophil, per 1% increased, *n =* 110                  0.043             1.068               1.002   1.138    --      --       --      --
  Lymphocyte, per 1% increased, *n =* 108                  0.010             0.859               0.766   0.964    --      --       --      --
  Hemoglobin, per 1 g/L increased, *n =* 109               0.068             0.977               0.953   1.002    --      --       --      --
  LDH, ref = \>214 U/L, *n =* 116                          0.059             7.452               0.927   59.900   --      --       --      --
  Albumin, ref = \>25 g/L, *n =* 116                       0.083             5.000               0.812   30.785   --      --       --      --
  Total cholesterol, ref = \>5.18 mmol/L, *n =* 116        0.970             0.960               0.111   8.306    --      --       --      --
  NT-proBNP elevated, ref = normal, *n =* 116              0.009             5.218               1.509   18.039   --      --       --      --
  hs-cTnI elevated, ref = normal, *n =* 116                0.004             6.429               1.816   22.753   --      --       --      --
  eGFR, ref = \<60 mL/min/1.73 m^2^, *n =* 116             0.001             16.833              3.197   88.624   0.016   13.451   1.617   111.891
  Coagulation disorder, ref = normal, *n =* 116            0.019             4.592               1.279   16.488   --      --       --      --
  D-dimer, ref = \>1 μg/mL, *n =* 116                      0.029             10.185              1.269   81.767   --      --       --      --

*Multivariable model performance (area under curve \[AUC\], Hosmer and Lemeshow goodness-of-fit test): AUC 0.849 (95% CI 0.729--0.968), χ^2^ = 1.231, p = 0.540. Continuous variables were per 1 unit increased. IL, interleukin; TNF-α, tumor necrosis factor-α; PCT, procalcitonin; hSCRP, high-sensitivity C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; LDH, lactic dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time. NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-cTnI, high-sensitivity cardiac troponin I*.

Discussion {#s4}
==========

The present retrospective cohort study identified several risk factors for COVID-19-related AKI. In particular, COVID-19 clinical classification, procalcitonin more than 0.1 ng/mL, and eGFR \<60 mL/min/1.73 m^2^. Additionally, in univariable analysis, sex, IL-2R, IL-10, TNF-α, neutrophil percentage, lymphocyte percentage, NT-proBNP, hs-cTnI, coagulation disorder, and D-dimer were associated with kidney injury.

Reviewing the previous published literature on COVID-19 (summarized in [Table 5](#T5){ref-type="table"}), patients with COVID-19 presented varying degrees of renal injury, with incidence varies from 0.5 to 28.8%. The incidence of AKI was lower among mild COVID-19 cases, while that of severe or critical cases was increased ([@B10], [@B14], [@B17]--[@B25]). In the present study, five (71.4%) patients with AKI of the sCr elevated group were diagnosed as the critical cases on admission, and four (80.0%) of five in-hospital AKI occurring after the condition worsened (as two developing respiratory failure and two acute respiratory distress syndrome). We found increasing odds of COVID-19-related kidney injury associated with the COVID-19 clinical classification. In the Chinese management guideline for COVID-19 (trial version 7.0) ([@B12]), oxygen saturation is the key parameter of clinical classification. Moreover, decreased oxygen saturation was observed in patients with AKI in the present study as well. Patients with COVID-19 may suffer kidney damage due to hypoxia. During acute hypoxemia, adenosine levels increase as adenosine triphosphate (ATP) hydrolysis exceeds synthesis resulting in intrarenal vasoconstriction, decreased renal perfusion, and drop of glomerular filtration rate ([@B26]). What is more, we also observed that eGFR decreased in COVID-19 patients resulting from heart failure. Based on our data, eGFR \<60 mL/min/1.73 m^2^ was proven to be significant.

###### 

Review of the COVID-19 related kidney impairment.

                          ***N***   **Pre-existing renal conditions**     **COVID-19-related kidney impairment**   **Notes**
  ----------------------- --------- ------------------------------------- ---------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Li et al. ([@B10])      59        --                                    --                                       32/51 exhibited proteinuria, Cre elevated in 11/59, Bun elevated in 16/59; 27/27 exhibited radiographic abnormalities of the kidneys
  Cheng et al. ([@B14])   710       --                                    22 AKI                                   On admission, sCr elevated in 110/710, 44% have proteinuria hematuria and 26.9% have hematuria; mortality of inpatients with elevated baselines Cr was 30.9%
  Yang et al. ([@B17])    52        --                                    15 AKI                                   sCr elevated significantly in survivors
  Xu et al. ([@B18])      62        1                                     --                                       sCr elevated in 2/62 of time since symptom onset ≤10 days group
  Wang et al. ([@B19])    138       4                                     5 AKI                                    Bun and sCr elevated significantly in ICU group (vs. non-ICU group)
  Shi et al. ([@B20])     81        --                                    3 CRF                                    --
  Huang et al. ([@B21])   41        --                                    3 AKI                                    sCr elevated in 4/41 (2/41 of ICU group, 2/41 of non-ICU group)
  Guan et al. ([@B22])    1,099     8                                     6 AKI                                    sCr elevated in 12/752 (16/614 of non-severe group, 6/138 of severe group)
  Chen et al. ([@B23])    99        --                                    3 AKI                                    Bun increased in 6/99, decreased in 17/99; sCr increased in 3/99, decreased in 21/99
  Chan et al. ([@B24])    7         --                                    --                                       Bun elevated in 2/7
  Diao et al. ([@B25])    85        5                                     23 ARF                                   Elder patients (≥60 years old) were easier to develop ARF; perished cases have a rapid decrease of eGFR but quickly boosting ccr and bun; H&E staining: severe acute tubular necrosis; immunohistochemistry: SARS-CoV-2 NP antigen accumulated in kidney tubules.
  Our study               116       --[^\*^](#TN2){ref-type="table-fn"}   12 AKI                                   sCr elevated in 21/116, 12(10.3%) AKI (5 in-hospital AKI); increasing odds of AKI associated with COVID-19 clinical classification, procalcitonin more than 0.1 ng/mL, and eGFR \<60 mL/min/1.73 m^2^

*Three patients excluded from the study, as one case receiving regular maintenance dialysis, one diabetic nephropathy, one nephrotic syndrome. AKI, acute kidney injury; ICU, intensive care unit; Bun, blood urea nitrogen; sCr, serum creatinine; Cre, plasma creatinine; CRF, chronic renal failure; ARF, acute renal failure; eGFR, estimated glomerular filtration rate; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; NP, nucleocapsid protein; H&E staining and hematoxylin--eosin staining*.

Previous studies had discussed the role of cytokine storm in the pathogenesis of severe viral pneumonia caused by SARS-CoV ([@B27]). Virus-induced cytokines might exert indirect effects on renal tissue. The autopsies of COVID-19 suggested cytokine storms in patients ([@B28]). In the present study, IL-2R, IL-6, TNF-α, and hs-CRP were significantly higher than the normal range and higher in the AKI group, and PCT more than 0.1 ng/mL was found to be associated with COVID-19-related AKI. According to a recent meta-analysis study, serial PCT measurement may play a role for predicting evolution toward a more severe form of disease ([@B29]).

Impaired renal function could recover, receiving clinical intervention, including active antiviral treatment, vasoactive agent for increasing renal perfusion, and advanced respiratory support for improving oxygen saturation. It is necessary to timely apply renal replacement therapy or blood purification in severe cases with COVID-19, complicated with AKI, systemic inflammatory response syndrome (SIRS), or multiple-organ dysfunction syndromes (MODS). Blood purification techniques, including plasma exchange, adsorption, perfusion, and filtration, in particular CRRT, played an important role in the rescue and treatment of severe acute respiratory syndromes (SARS), Middle East Respiratory Syndrome (MERS), and other sepsis ([@B30], [@B31]). The efficacy and safety of antiviral drugs for COVID-19 require further confirmation by clinical experiments, and clinicians should thus be aware of the potential dosage adjustments and renal adverse events ([@B32]).

As far as we know, the present study was the first to identify the potential risk factors of COVID-19-related AKI and providing treatment experience for the clinical management of COVID-19-related AKI. Our study has some limitations. Due to the retrospective study design, not all needed laboratory findings were collected, such as urine routine test and SARS-CoV-2 antibody. Therefore, their role might be underestimated. The sample size might limit the interpretation of our findings. Considering the total number of AKI (*n* = 12) in our study and overfitting in the model are almost inevitable. The sample size of this study does not meet the requirements of EPV (event per variable), so the results may not be robust. However, such patients are rare and the results are somewhat interpretable, we still present the results of the study. The findings should be interpreted as exploratory and descriptive; therefore, a multicenter, large sample size, and prospective study will be required. Continued observations of the natural history of the COVID-19-related kidney injury are needed.

Conclusion {#s5}
==========

Patients with COVID-19 presented varying degrees of kidney injury, and the AKI was likely to be related to multiorgan failure rather than the kidney tropism of SARS-CoV-2. The potential risk factors of COVID-19 clinical classification, eGFR, and procalcitonin could help clinicians to identify patients with kidney injury at an early stage.
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